Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
coagulation factor ix recombinant
- Development stage
- Approved
- Lead developer
- Pfizer
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
Coagulation factor IX (recombinant) is a biosynthetic protein produced using recombinant DNA technology to replicate the naturally occurring human coagulation Factor IX. It is indicated for the treatment, control, prevention, and reduction of bleeding episodes in patients with hemophilia B (congenital Factor IX deficiency or Christmas disease), as well as for preventing bleeding during surgery in these patients. The drug works by replacing missing or deficient Factor IX to restore normal blood clotting through its role in the coagulation cascade. Recombinant forms are not derived from human plasma but are produced in genetically engineered cell lines such as Chinese hamster ovary cells[1][2][8]. This approach reduces risks associated with pathogen transmission compared to plasma-derived products and is considered standard of care for hemophilia B management[5]. Major brand names include Benefix (Pfizer), Idelvion (CSL Behring), Ixinity (Medexus Pharma), and Rixubis (Takeda)[1][2][3].
- Brand names
- BenefixIdelvionIxinityRixubis
- Other names
- recombinant factor ixfactor ix recombinant
02
Targets
F9 (Coagulation Factor IX)
Beyond the preview
Go deeper on coagulation factor ix recombinant.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on coagulation factor ix recombinant.